Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $40.6 million.

  • Viridian Therapeutics, Inc.\DE's Accumulated Expenses rose 1696.99% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 1696.99%. This contributed to the annual value of $45.7 million for FY2024, which is 8969.22% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Accumulated Expenses stood at $40.6 million for Q3 2025, which was up 1696.99% from $35.3 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Accumulated Expenses' 5-year high stood at $45.7 million during Q4 2024, with a 5-year trough of $10.3 million in Q3 2021.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Accumulated Expenses value was $21.4 million (recorded in 2023), while the average stood at $23.0 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 36854.3% in 2021, then crashed by 943.28% in 2022.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Accumulated Expenses (Quarter) stood at $11.0 million in 2021, then surged by 70.87% to $18.8 million in 2022, then grew by 28.05% to $24.1 million in 2023, then surged by 89.69% to $45.7 million in 2024, then dropped by 11.15% to $40.6 million in 2025.
  • Its last three reported values are $40.6 million in Q3 2025, $35.3 million for Q2 2025, and $29.6 million during Q1 2025.